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Why should cell biologists study microbial 
pathogens?
Matthew D. Welch
Department of Molecular & Cell Biology, University of California, Berkeley, Berkeley, CA 94720
ABSTRACT One quarter of all deaths worldwide each year result from infectious diseases 
caused by microbial pathogens. Pathogens infect and cause disease by producing virulence 
factors that target host cell molecules. Studying how virulence factors target host cells has 
revealed fundamental principles of cell biology. These include important advances in our un-
derstanding of the cytoskeleton, organelles and membrane-trafficking intermediates, signal 
transduction pathways, cell cycle regulators, the organelle/protein recycling machinery, and 
cell-death pathways. Such studies have also revealed cellular pathways crucial for the immune 
response. Discoveries from basic research on the cell biology of pathogenesis are actively 
being translated into the development of host-targeted therapies to treat infectious diseas-
es. Thus there are many reasons for cell biologists to incorporate the study of microbial 
pathogens into their research programs.
INTRODUCTION
Infectious diseases cause approximately one quarter of all deaths 
worldwide each year (Fauci and Morens, 2012). These include the 
“big three”—HIV/AIDS, tuberculosis, and malaria—which account 
for 10% of all deaths. They also include emerging diseases such as 
Ebola, Middle East Respiratory Syndrome, and methicillin-resistant 
Staphylococcus aureus. Infections are caused by microbial patho-
gens from different domains of the tree of life—viruses, bacteria, or 
eukaryotes. All share the ability to colonize their hosts and cause 
pathology through their interactions with host cells.
To influence host cells, each pathogen produces a distinct set of 
virulence factors that target specific host cell structures, pathways, 
and molecules. The function of virulence factors differs depending 
on where the pathogen establishes residence (Figure 1). Extracellu-
lar pathogens reside around or in contact with host cells but resist 
internalization into cells. They produce virulence factors that inhibit 
phagocytosis and otherwise disable elements of the immune re-
sponse. Intracellular pathogens instead encourage their internaliza-
tion into host cells, grow within a preferred cellular compartment or 
organelle, and then exit the cell to disseminate the infection. They 
produce virulence factors that promote phagocytosis, enable move-
ment to their preferred compartment, manipulate membrane traf-
ficking and autophagy to resist killing and permit growth and repli-
cation, and exit the cell to promote spread.
The cellular and molecular targets of pathogen virulence factors 
are the same systems studied by most cell biologists. They include: 
the cytoskeleton, organelles and membrane-trafficking intermedi-
ates, signal transduction pathways, cell cycle regulators, the organ-
elle and protein recycling machinery, and cell-death pathways 
(Table 1). Studying the mechanisms by which virulence factors target 
host cells has two important impacts. First, such studies reveal cru-
cial mechanisms of infection. Second, these studies aid in the eluci-
dation of fundamental cellular mechanisms—for example, tyrosine 
kinase signaling or actin-based motility, to name a very few.
The study of pathogen interactions with host cells also has practi-
cal impacts on fighting infectious diseases. One is advancing our 
understanding of immunity. Immune cells are often the targets of 
pathogen virulence factors, and understanding the interactions of 
pathogens with immune cells enhances the development of effec-
tive immune-based therapies for infections. Another is identifying 
cellular molecules crucial for infection, which are then exploited as 
targets of drugs to treat infectious diseases.
In this Perspective, I provide concrete answers to the basic ques-
tion posed in the title: Why should cell biologists study microbial 
pathogens? Along the way, I explore three smaller questions: What 
have we learned about basic cell biology from studying pathogens 
and their virulence factors? What has studying the cell biology of 
host–pathogen interactions taught us about immunity? How has 
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inhibit phagocytosis by producing virulence 
factors that disable Rho, Rac, and/or Cdc42, 
highlighting the generality of this patho-
genic strategy (Lemichez and Aktories, 
2013). Bacterial toxins continue to be im-
portant tools for revealing the functions of 
Rho GTPases in cells.
The study of pathogens that mobilize ac-
tin for movement has also led to the discov-
ery of fundamental mechanisms of cytoskel-
etal dynamics and regulation. Such 
pathogens include the bacteria Listeria 
monocytogenes, Shigella flexneri, and 
Escherichia coli, which cause food-borne ill-
nesses, as well as vaccinia virus, which is the 
smallpox vaccine strain. These microbes un-
dergo actin-based motility either within or 
on the surface of cells, which enables cell-
to-cell spread during infection (Welch and 
Way, 2013). Through biochemical reconsti-
tution of L. monocytogenes and/or S. flex-
neri motility, the host Arp2/3 complex and 
its activators (the WASP family proteins) 
were revealed as key actin-nucleating fac-
tors for bacterial pathogens and host cells 
(Welch et al., 1997, 1998), and a minimal set 
of proteins that is sufficient to drive actin-
based motility was defined (Loisel et al., 
1999). Moreover, the study of enteropatho-
genic/enterohemorrhagic E. coli and vac-
cinia virus, which induce actin assembly 
from outside the cell through the plasma 
membrane, revealed important roles for ty-
rosine kinase signaling and protein clustering in regulating actin as-
sembly (Frischknecht et al., 1999; Campellone et al., 2008).
Studying pathogens has also led to fundamental advances in the 
field of membrane trafficking. A classic example involves the extra-
cellular bacterial pathogens C. botulinum, mentioned above, as well 
as Clostridium tetani, which causes the paralytic disease tetanus. In 
addition to the C3 exoenzyme, C. botulinum produces botulinum 
toxins A–G (type A is familiarly known as Botox), and C. tetani se-
cretes tetanus toxin. These toxins specifically cleave SNARE protein 
components of the vesicle fusion machinery, including VAMP, SNAP-
25, and syntaxin (Link et al., 1992; Schiavo et al., 1992; Blasi et al., 
1993a,b). Microinjection of nerve cells with these toxins showed that 
SNARE molecules are critical for neurotransmitter release via vesicle 
fusion with the plasma membrane (Schiavo et al., 1992; Blasi et al., 
1993b). Preventing neurotransmitter release results in the paralysis 
caused by botulinum and tetanus toxins. In a contemporary study, it 
was revealed that SNARE proteins form a complex that is sufficient 
to mediate vesicle docking and fusion (Söllner et al., 1993). Thus 
bacterial toxins were used in discovering fundamental mechanisms 
of membrane fusion and vesicular transport.
Advances in our understanding of how membrane-trafficking 
pathways contribute to repairing plasma membrane wounds 
(Sonnemann and Bement, 2011) have also come from the study of 
intracellular pathogens. A classic example is Trypanosoma cruzi, a 
eukaryotic parasite and the causative agent of Chagas disease, 
which in its chronic form can cause cardiovascular and intestinal ill-
ness. As the T. cruzi parasite contacts the plasma membrane of a 
host cell before invasion, intracellular Ca2+ is elevated, and cellular 
lysosomes are recruited to the point of contact between the parasite 
identifying cellular targets of pathogens led to the development of 
therapeutic agents to treat infection?
WHAT HAVE WE LEARNED ABOUT BASIC CELL BIOLOGY 
FROM STUDYING PATHOGENS AND THEIR VIRULENCE 
FACTORS?
The study of how pathogens and their virulence factors impact host 
cells has been fertile ground for uncovering basic cell biological 
principles and mechanisms. Such discoveries have enhanced our 
understanding of the many structures, pathways, and molecules 
that are commonly exploited by pathogens during infection.
One area of cell biology in which the study of pathogens has 
enabled fundamental advances is the cytoskeletal field. Extracellular 
bacterial pathogens often target actin or its regulators by secreting 
toxins that translocate across cellular membranes to inhibit phago-
cytosis by immune cells (Lemichez and Aktories, 2013). An example 
is Clostridium botulinum, which causes the paralytic illness botulism. 
C. botulinum produces several secreted toxins, including C3 toxin, 
which enters host cells and ADP-ribosylates and inactivates the Rho 
family GTPase Rho (paralysis is caused by a separate toxin, as dis-
cussed below; Narumiya et al., 1988; Aktories et al., 1989). By exam-
ining the effect of microinjecting C3 toxin into cells, Alan Hall and 
coworkers discovered that Rho signals to promote the formation of 
focal adhesions and stress fibers (Chardin et al., 1989; Paterson 
et al., 1990; Ridley and Hall, 1992). Sadly, Alan passed away earlier 
this year in the prime of his career. Similar studies showed that Rho 
family proteins are also required for phagocytosis (Hall, 2012). Many 
bacteria, such as Clostridium difficile, the leading cause of hospital-
acquired diarrhea, or Yersinia pestis, the causative agent of plague, 
FIGURE 1: Pathogen virulence factors influence cellular pathways and structures. Extracellular 
pathogens produce virulence factors that act at a distance or on contact with a host cell. These 
virulence factors inhibit cellular processes (indicated by red) including phagocytosis and 
secretion. In contrast, intracellular pathogens produce virulence factors that promote intimate 
interactions with host cells. These activate cellular processes (indicated by green), including 
phagocytosis, intracellular movement to a preferred compartment or organelle, and cell-to-cell 
spread. Virulence factors can also either activate or inactivate cellular processes (indicated by 
orange) to prevent microbial killing and enable growth and replication. These pathways include 
those involved in membrane trafficking, autophagy, cell death, and cell cycle regulation.
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influenced by the study of viruses (Martin, 2004). Famous examples 
are the Rous sarcoma virus (RSV), which causes sarcomas in chick-
ens, and Abelson murine leukemia virus (A-MuLV), which causes 
lymphosarcomas in mice. The capacity of RSV to transform normal 
cells into tumor cells was found to be associated with the viral src 
gene and its product v-Src (Brugge and Erikson, 1977; Weiss et al., 
1977). The v-Src protein and the v-Abl protein from A-MuLV were 
subsequently shown to be tyrosine kinases (Hunter and Sefton, 
1980; Witte et al., 1980), the first discovery of this protein class. Cel-
lular homologues of these proteins, c-Src and c-Abl, were soon 
identified (Stehelin et al., 1976; Shalloway et al., 1981; Heisterkamp 
et al., 1982), demonstrating that viral oncogenes are derived from 
cellular counterparts. It was also soon recognized that the human 
ABL1 gene, which encodes c-Abl, participates in the Philadelphia 
chromosomal translocation, which is commonly associated with leu-
kemias (de Klein et al., 1982). Thus viruses were key to demonstrat-
ing the importance of tyrosine kinases in signaling in normal and 
cancer cells and the roles of oncogenes in cancer. Future studies of 
pathogens will continue to reveal ways in which diverse signaling 
pathways and proteins influence normal cell physiology and 
disease.
WHAT CAN STUDYING THE CELL BIOLOGY OF 
HOST–PATHOGEN INTERACTIONS TEACH US ABOUT 
IMMUNITY?
Cells of the immune system are often targeted by pathogens to 
avoid or subvert immune defenses. Certain facets of the interaction 
between pathogens and immune cells lie at the interface between 
the fields of immunology and cell biology. The study of such areas is 
of increasing importance in understanding general mechanisms of 
pathogenesis, and may prove particularly relevant in harnessing the 
and host cell. Surprisingly, lysosomes participate in exocytosis at the 
invasion site, which facilitates invasion (Tardieux et al., 1992, 1994). 
It was later revealed that the Ca2+-dependent fusion of lysosomes 
(Reddy et al., 2001) and other organelles (Shen et al., 2005) plays a 
key role in repairing plasma membrane wounds in uninfected cells. 
Along with work on T. cruzi, studying how intracellular bacterial 
pathogens such as Legionella pneumophila, the causative agent of 
Legionnaire’s disease, manipulate membrane-trafficking pathways is 
advancing our understanding of these pathways in uninfected cells 
(Asrat et al., 2014).
Cell cycle regulatory mechanisms have also been exposed 
through the investigation of virus interactions with host cells (Bagga 
and Bouchard, 2014). Classic examples involve the study of DNA 
tumor viruses, which include adenovirus, human papilloma virus, and 
SV40. These viruses rely on the host DNA replication machinery, and 
thus they induce cell cycle progression into S phase to favor viral 
DNA replication. A key discovery was that these viruses encode pro-
teins, such as E1A from adenovirus, that bind to the tumor-suppres-
sor protein pRb and related proteins (Whyte et al., 1988). The role of 
pRb as a negative regulator of cell cycle progression was subse-
quently revealed when it was found that E1A binding to pRb com-
petes with and releases the bound transcription factor E2F, which 
turn activates the expression of cell cycle regulatory genes that pro-
mote entry into S phase (Bagchi et al., 1991; Bandara and La 
Thangue, 1991; Chellappan et al., 1991; Raychaudhuri et al., 1991). 
Other viruses target different cell cycle regulators, including Cdks 
and cyclins (Bagga and Bouchard, 2014), and studying how viruses 
manipulate host cells will continue to reveal cell cycle regulatory 
mechanisms.
Finally, our understanding of signal transduction pathways and 
their contribution to diseases like cancer has also been heavily 
Pathway/structure Pathogenic process Pathogens Host targets References
Cytoskeleton Inhibit phagocytosis Many extracellular pathogens, e.g., 
Clostridium spp., Yersinia spp.
Rho proteins, actin Lemichez and 
Aktories, 2013
Phagocytosis Most intracellular pathogens Rho proteins, signaling 
proteins, phagocytic 
proteins, actin
Pizarro-Cerdá and 
Cossart, 2006
Movement, spread Many pathogens, e.g., L. monocy-
togenes, S. flexneri, E. coli, vaccinia 
virus
Arp2/3 complex, 
signaling proteins,  
actin
Welch and Way, 
2013
Membrane 
trafficking
Growth/replication Many extracellular pathogens, e.g., C. 
botulinum, C. tetani; many intracel-
lular pathogens, e.g., T. cruzi, L. pneu-
mophila
SNARE proteins, Rab 
proteins, Arf proteins
Asrat et al., 2014
Cell cycle Growth/replication Many viruses, e.g., adenovirus, human 
papilloma virus, SV40
pRb, cyclins, Cdks Bagga and 
Bouchard, 2014
Signal transduction Growth/replication Many pathogens, e.g., vaccinia virus, 
RSV, A-MuLV
Tyrosine kinases, other 
kinases, GTPases, lipid 
modifiers
Martin, 2004
Autophagy Growth/replication Many intracellular pathogens, e.g., S. 
Typhimurium, L. monocytogenes, S. 
flexneri, M. tuberculosis
NDP52, p62, optineurin Mostowy, 2014; 
Sorbara and 
Girardin, 2015
Cell death Growth/replication Many pathogens, e.g., S. 
Typhimurium, P. falciparum
Caspase-1, inflamma-
somes, p53, Bcl-2
Guo et al., 2015
This table is meant to provide important and interesting examples without being comprehensive.
TABLE 1: Summary of cellular pathways targeted by pathogens.
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pacted DNA fragmentation, and loss rather than maintenance of 
plasma membrane integrity (Brennan and Cookson, 2000). This 
mechanism of cell death was subsequently called pyroptosis, which 
is a proinflammatory cell death, to distinguish it from apoptosis, 
which is anti-inflammatory. Subsequent studies showed that cas-
pase-1 activation involves a multiprotein complex called an inflam-
masome (Martinon et al., 2002), of which there are multiple variet-
ies with different functions in innate immunity and inflammation 
(Guo et al., 2015). In addition to their roles in infection, inflamma-
somes also play an important role in metabolic and neurological 
diseases (Guo et al., 2015). The continued study of inflammasomes 
will enhance our understanding of inflammatory responses to infec-
tion and of the role of inflammation in normal cell function and 
disease.
HOW HAS IDENTIFYING CELLULAR TARGETS OF 
PATHOGENS LED TO THE DEVELOPMENT OF 
THERAPEUTIC AGENTS TO TREAT INFECTION?
There are two predominant approaches for combating infectious 
diseases. One is to stimulate the immune system to prevent or re-
duce the impact of infection, for example, through vaccination. An-
other is to reduce or eliminate an existing infection with drugs that 
kill the infectious agent and/or enhance the immune response. 
Studying the cell biology of pathogenesis is contributing to both of 
these therapeutic avenues.
An interesting example involves an emerging connection be-
tween autophagy and vaccine efficacy. The bacillus Calmette-
Guerin (BCG) vaccine, used to combat tuberculosis caused by the 
intracellular pathogen Mycobacterium tuberculosis, consists of an 
attenuated strain of the related bacterium Mycobacterium bovis. 
BCG has a protective effect against meningitis and disseminated 
tuberculosis in children but does not prevent primary infection with 
M. tuberculosis or reactivation of pulmonary infection, which is the 
main route of spread of the disease. Thus a more effective vaccine 
is needed. Interestingly, augmenting autophagy with rapamycin 
was found to enhance presentation of a BCG antigen by antigen-
presenting cells and enhance protection against M. tuberculosis 
infection in animal model (Jagannath et al., 2009). A similar phe-
nomenon was observed for the yellow fever vaccine YF-17D, a live 
attenuated virus that, in contrast with BCG, is almost always effec-
tive in protecting against infection with the yellow fever virus. It was 
shown that YF-17D stimulated expression of the kinase GCN2, 
which in turn stimulated dendritic cells to initiate autophagy and 
enhanced antigen presentation to T-cells (Ravindran et al., 2014). 
These findings suggest that stimulating autophagy may be a gen-
eral strategy for enhancing antigen presentation and vaccine 
efficacy.
In cases in which vaccination is not possible or fails to confer 
protection, antiviral, antibacterial, and antiparasitic drugs are com-
monly used to treat infections. These drugs generally target 
pathogen molecules that are both essential for pathogen growth 
and are distinct from host molecules, enhancing the selective tox-
icity of the drug for the infectious agent while minimizing side ef-
fects on the host. This raises the following question: Can host cell 
components that are important for pathogenesis also be effective 
drug targets for treating infectious diseases? The answer is yes, 
and it is noteworthy that targeting host molecules appears to be 
an emerging strategy for the development of drugs to treat 
infections.
Targeting host molecules has advanced the furthest in develop-
ing treatments for viral infections. Prime examples are drugs that 
target host cell receptor molecules and prevent viral entry. Maraviroc 
immune system to fight infection. In this section, I highlight emerging 
areas of intersection between basic cellular pathways and the innate 
immune response to pathogens. In the subsequent section, I dis-
cuss how studying these areas impacts the development of thera-
peutics to treat infectious diseases.
Autophagy has emerged as a process that is of central inter-
est in the fields of cell biology and immunology, and research in 
both disciplines has synergized to reveal key ways in which au-
tophagy impacts basic cell function and disease. Studies by cell 
biologists have uncovered the importance of autophagy in main-
taining homeostasis during normal, stressful, or disease condi-
tions, and have identified important molecular players in this 
pathway (Boya et al., 2013). Immunologists have discovered that 
autophagy of pathogens (also called xenophagy) is an important 
arm of the innate immune response that promotes intracellular 
pathogen sequestration in autophagosomes and their degrada-
tion in lysosomes (Huang and Brumell, 2014; Sorbara and 
Girardin, 2015).
An example of how studying pathogens has advanced our under-
standing of autophagy mechanisms involves the response to infec-
tion by the intracellular pathogen Salmonella enterica serovar Ty-
phimurium (S. Typhimurium), a common cause of diarrheal illness. S. 
Typhimurium normally resides within an endosome-like compartment 
called the Salmonella-containing vacuole (SCV). However, observa-
tion of the bacteria that occasionally damage the SCV and escape 
into the cytosol enabled the discovery of previously unknown mecha-
nisms by which pathogens are targeted to autophagy. These include 
marking bacteria in the cytosol with ubiquitin (Thurston et al., 2009) 
and marking those in damaged SCVs with the lectin galectin-8, which 
recognizes glycans on damaged vacuoles (Thurston et al., 2012). 
Both galectin-8 and ubiquitin are then recognized by adapter pro-
teins (including NDP52, p62, and optineurin), which recruit LC3 and 
initiate autophagosome formation (Thurston et al., 2009, 2012; 
Zheng et al., 2009; Wild et al., 2011). In addition to their roles in infec-
tion, these same pathways may be involved in targeting damaged 
organelles in uninfected cells (Huang and Brumell, 2014; Sorbara and 
Girardin, 2015) and in removing protein aggregates, for example, 
those associated with neurodegenerative diseases (Rubinsztein et al., 
2015).
A second example highlights how the study of pathogens can 
reveal new pathways that influence autophagy, such as an emerging 
link between cytoskeletal elements and the autophagy machinery 
(Mostowy, 2014). In the case of L. monocytogenes, the ability of the 
bacterial ActA protein to recruit actin-polymerizing factors masks 
the bacteria from ubiquitination and the initiation of autophago-
some formation (Yoshikawa et al., 2009). This suggests a potential 
role for actin in autophagy inhibition. In contrast, for S. flexneri, re-
cruitment of actin promotes the subsequent recruitment of septin 
proteins, which cage the bacteria and are crucial for autophagy 
(Mostowy et al., 2010, 2011). Thus, in the case of S. flexneri, actin 
and septins play a stimulatory role in autophagy. Deciphering the 
roles of cytoskeletal elements in autophagy regulation and the in-
nate immune response should be an active area of future 
investigation.
Beyond autophagy, the study of pathogens has revealed previ-
ously unappreciated pathways for regulating programmed cell 
death that are integral to innate immunity and inflammation. One 
such pathway was discovered by studying cell death induced by S. 
Typhimurium. It was noted that S. Typhimurium infection induced 
cell death in macrophages that was dependent on caspase-1 (Hersh 
et al., 1999). Moreover, the characteristics of death were distinct 
from apoptosis in key respects, including diffuse rather than com-
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CONCLUSIONS AND FUTURE DIRECTIONS
In writing this Perspective, I hope to encourage cell biologists to 
study pathogens by collaborating with pathogenesis researchers or 
incorporating work on infectious diseases into their own research 
programs. Such investigations might focus on well-known patho-
gens or new and emerging infectious agents. The motivation may 
be a desire to reveal new biological principles or to better understand 
and treat important diseases. Regardless of the choice of pathogen 
or source of motivation, future studies by cell biologists will uncover 
new ways in which pathogens influence host cell pathways and 
structures, and new cell biological mechanisms that operate under 
normal circumstances and in various disease states. Future studies 
will also contribute to the development of new vaccines and drugs 
that target host cell proteins to prevent or treat infections. Therefore 
basic and translational research at the interface between microbiol-
ogy, cell biology, and immunology will be an increasingly important 
source of information and innovation relevant to biology in general 
and infectious disease in particular.
is a Federal Drug Administration (FDA)-approved drug that is used 
in combination therapy to treat HIV infection. It inhibits viral entry 
into cells by binding to the chemokine- and HIV-receptor CCR5 
(Wood and Armour, 2005). Other inhibitors of host proteins in-
volved in HIV infection are also in development (Arhel and Kirch-
hoff, 2010). Moreover, inhibitors of the cellular receptors for other 
viruses have been identified. A small molecule that inhibits cellular 
infection with Ebola virus, the causative agent of a dramatic hemor-
rhagic fever, works by binding to the endosomal protein NPC1 
(Côté et al., 2011). In fact, the identification of this inhibitor revealed 
that NPC1 is a crucial factor for Ebola virus infection. A more recent 
study identified an engineered protein that inhibits infection with 
the influenza virus, which causes flu, by binding to sialic acid, which 
is used as a receptor for virus entry (Connaris et al., 2014). One in-
tranasal dose of this inhibitor protected mice from an otherwise le-
thal dose of the 2009 pandemic H1N1 virus, while also enabling 
sufficient viral replication to potentially protect the animals from fu-
ture infection.
Antibacterial agents that target host cell molecules are also be-
ing explored. Such agents will be particularly useful in cases for 
which there is no effective vaccine, and/or resistance to conven-
tional antibiotics is common, as with M. tuberculosis. A recent fruit-
ful approach was to screen through a library of bioactive small mol-
ecules known to target host proteins for those that restrict the 
growth of M. tuberculosis (Stanley et al., 2014). This identified 
compounds that affect several protein classes, including G pro-
tein–coupled receptors, ion channels, membrane transport pro-
teins, kinases, and anti-inflammatories. Through this and other 
studies, a list can be compiled of FDA-approved drugs that target 
host molecules and inhibit M. tuberculosis infection, including the 
antidepressants fluoxetine (Prozac; Stanley et al., 2014) and nor-
triptyline (Sundaramurthy et al., 2013); the epidermal growth factor 
receptor kinase inhibitor gefitinib (Stanley et al., 2014) and Abl ki-
nase inhibitor imatinib (Napier et al., 2011; Bruns et al., 2012); and 
the antiseizure medication carbamazepine (Schiebler et al., 2015). 
A common theme linking these drugs is that they induce autoph-
agy, again highlighting the potential utility of autophagy-stimulat-
ing drugs in the prevention and treatment of infections (Rubinsztein 
et al., 2015).
Finally, targeting components of the host cell may also prove 
fruitful for combating infection by intracellular parasites such as Plas-
modium falciparum and other Plasmodium species, which are the 
causative agents of malaria. During infection of host hepatocytes, 
Plasmodium suppresses the expression of the cell cycle regulator 
and proapoptotic protein p53 and increases the expression of the 
antiapoptotic protein Bcl-2, thus preventing host cell apoptosis 
(Kaushansky et al., 2013). It was recently found that counteracting 
the parasite’s anti-apoptotic program by treatment with the small 
molecule p53 activator Nutlin-3 and/or the Bcl-2 inhibitors Obato-
clax or ABT-737, all of which are under study as anticancer therapeu-
tics, delayed or prevented onset of disease caused by P. falciparum 
(Douglass et al., 2015). This reveals the potential therapeutic value 
of drugs that target host cell death molecules for treating infectious 
disease.
Thus it appears that developing drugs that target host compo-
nents is a viable strategy to combat infectious diseases, and this 
may prove complementary to the traditional approach of develop-
ing antimicrobials that target pathogen proteins. Although potential 
drawbacks of such a strategy include the risk of toxicity to the host, 
potential benefits may include an increased flexibility in developing 
combination therapies and a reduced capacity of the pathogens to 
become resistant to drug treatment.
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